Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.0K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

655
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
655
Cancer Vaccines01:30

Cancer Vaccines

1.1K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
Cancer Therapies02:49

Cancer Therapies

10.2K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Direct Access to Sulfonamidated-1,4-Benzoquinones via Sulfonamidation of Aryl Alcohol-Derived Quinone Monoacetals.

Organic letters·2026
Same author

Fragility of Randomized Controlled Trials for Fluid Resuscitation in Acute Pancreatitis.

Digestive diseases and sciences·2026
Same author

Clinical practice pattern of management of plasma cell dyscrasia for kidney transplant candidates and recipients in the United States.

Journal of onco-nephrology·2026
Same author

Surveillance Strategies in Follicular Non-Hodgkin's Lymphoma's Using Molecular and Genetic Markers Improve Cost-efficiencies Over Routine Imaging Studies.

American journal of clinical oncology·2026
Same author

Molecular, Transcriptomic, and Proteomic Characterization of <i>Plasmodium</i> Infections that Evade Detection by Rapid Diagnostic Tests in Mizan Aman, Ethiopia.

medRxiv : the preprint server for health sciences·2026
Same author

Structure characterization with NMR molecular networking.

Communications chemistry·2025

Related Experiment Video

Updated: Feb 17, 2026

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.7K

Excellent response to chemotherapy post immunotherapy.

Ashish D Dwary1, Samip Master1, Abhishek Patel1

  • 1Department of Medicine, Division of Hematology-Oncology, Louisiana State University Health Sciences Center, Shreveport, LA, USA.

Oncotarget
|December 7, 2017
PubMed
Summary

Chemotherapy after immune checkpoint inhibitor therapy shows promise for cancer patients who have progressed. This sequence may improve treatment response and survival outcomes.

Keywords:
chemotherapyexcellent responseimmunotherapy

More Related Videos

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

12.4K
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.8K

Related Experiment Videos

Last Updated: Feb 17, 2026

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.7K
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

12.4K
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.8K

Area of Science:

  • Oncology
  • Immunotherapy
  • Cancer Treatment

Background:

  • Immune checkpoint inhibitors (ICIs) have transformed cancer care.
  • Optimal sequencing of therapies after ICI progression is an unmet need.
  • Investigating salvage chemotherapy post-ICI is crucial.

Purpose of the Study:

  • To evaluate the efficacy of salvage chemotherapy in patients progressing on ICIs.
  • To determine if chemotherapy sequencing after immunotherapy yields favorable outcomes.
  • To explore potential mechanisms behind enhanced chemotherapy response post-ICI.

Main Methods:

  • A case series of six patients with advanced malignancies (head and neck, NSCLC, lymphoma) progressing on ICIs.
  • All patients received third-line salvage chemotherapy.
  • ECOG performance status < 2 was a criterion for inclusion.

Main Results:

  • All six patients demonstrated excellent responses to salvage chemotherapy.
  • Most patients achieved a complete response in the third-line setting.
  • Chemotherapy following ICI failure proved highly effective.

Conclusions:

  • Salvage chemotherapy is a viable strategy after immunotherapy failure.
  • This approach can improve response rates, progression-free survival (PFS), and overall survival (OS).
  • Potential mechanisms include ICI-mediated immune modulation followed by chemotherapy-induced tumor cell death.